Internal Medicine, Infectious Disease · Oakland Park, FL
NPI
1104129634
Since 2010
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
4
Medicare group memberships
Hospitals
3
Hospital affiliations
1421 E Oakland Park Blvd, Suite 101
Oakland Park, FL, 33334
Phone (954) 565-0875
Groups this clinician bills Medicare through
Medicare paid, 2024
$91K
2,681 services
Medicare patients, 2024
294
Average age 70
Drug cost, 2024
$4.3M
2,176 prescriptions
Company payments, 2025
$155
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Patrick J Kenney was code 99233 (hospital e&m - subsequent), 573 times for 175 patients. In total Patrick J Kenney billed 2,681 services in 13 codes, and Medicare paid $91K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-12-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 573 | 175 | $95.04 | $54K |
| 99214 Office E&M - Established | Office | 136 | 91 | $97.37 | $13K |
| 99222 Hospital E&M - Initial | Facility | 81 | 78 | $105.82 | $8,571 |
| 99204 Office E&M - New | Office | 18 | 18 | $115.21 | $2,074 |
By year: 2022 $64K for 637 services; 2023 $85K for 901 services; 2024 $91K for 2,681 services.
Medicare prescription drug claims, 2024
In 2024, the drug Patrick J Kenney prescribed most often to Medicare patients was Descovy (Emtricitabine/Tenofov Alafenam), with 496 prescriptions and refills. In total Patrick J Kenney wrote 2,176 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Descovy Emtricitabine/Tenofov Alafenam | 496 | 504 | 95 | $1.0M |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 280 | 286 | 38 | $1.2M |
| Tivicay Dolutegravir Sodium | 98 | 98 | 12 | $306K |
| Emtricitabine-Tenofovir Disop Emtricitabine/Tenofovir (Tdf) | 74 | 92 | 21 | $5,410 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 58 | 62 | Under 11 | $241K |
| Prezcobix Darunavir/Cobicistat | 57 | 61 | Under 11 | $154K |
| Azithromycin Generic | 55 | 76 | 17 | $1,349 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 51 | 64 | 11 | $1,002 |
| Pifeltro Doravirine | 42 | 42 | Under 11 | $77K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 39 | 39 | Under 11 | $169K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 39 | 39 | Under 11 | $187K |
| Dovato Dolutegravir Sodium/Lamivudine | 37 | 37 | Under 11 | $115K |
| Juluca Dolutegravir/Rilpivirine | 36 | 44 | Under 11 | $161K |
| Ertapenem Ertapenem Sodium | 35 | 35 | 17 | $19K |
| Vancomycin Hcl Generic | 35 | 35 | 12 | $5,401 |
Brand drugs: 1,313 claims; generic drugs: 863 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Patrick J Kenney $155 ($155 in general payments such as food, travel and fees) from 2 companies. The largest payer was Gilead Sciences, Inc. with $125.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.